Real-life Data of Constitutional Von Willebrand Disease in Western France: Treatment Outcomes With the Recombinant Von Willebrand Factor
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 922
- 试验地点
- 5
- 主要终点
- Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity
研究概览
简要总结
The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center.
The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors
- •Patient included in the research database BERHLINGO
- •Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline)
- •Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers
排除标准
- •Patients under guardianship
结局指标
主要结局
Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity
时间窗: 4 years
Data collection for evaluation of Clotting factors quantities used by collection of treatments for severe hemorrhagic events
次要结局
未报告次要终点